Vimseltinib for Tenosynovial Giant Cell Tumor
MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Recruiting
Observational Study
Tenosynovial Giant Cell Tumor
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- Deciphera Pharmaceuticals, LLC · Industry
Who this trial is looking for
This trial is looking for people with tenosynovial giant cell tumor (TGCT) who are being treated with vimseltinib. Participants will provide information about their experiences with the treatment.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with TGCT.
- I have been prescribed vimseltinib or have decided to start it.
- I have given my consent and allowed access to my medical records.
You may not be able to join if
- I am currently in another clinical trial for vimseltinib.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.
This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participan…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Diagnosis of TGCT according to medical records
2. Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated.
3. Has provided informed consent and medical records release
Exclusion…
Contacts